Transimmune
D├╝sseldorf
About Transimmune
Transimmune is a provider of dendritic cell therapy, having discovered the physiological process by which dendritic cells are produced.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $5.0M
- Funding stage: Seed
- Last round: Seed (Sep 2023)
- Website: transimmune.com
- Phone: +49 21164136110
Industries & Categories
Biotechnology, Product Research
Social Profiles
Canonical: https://fsome.com/organization/transimmune-43755 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.